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Abstract
Molecular sensing in the lingual mucosa and in the gastro-intestinal tract play a role in the detection of ingested harmful
drugs and toxins. Therefore, genetic polymorphisms affecting the capability of initiating these responses may be critical for
the subsequent efficiency of avoiding and/or eliminating possible threats to the organism. By using a tagging approach in
the region of Taste Receptor 2R38 (TAS2R38) gene, we investigated all the common genetic variation of this gene region in
relation to colorectal cancer risk with a case-control study in a German population (709 controls and 602 cases) and in a
Czech population (623 controls and 601 cases). We found that there were no significant associations between individual
SNPs of the TAS2R38 gene and colorectal cancer in the Czech or in the German population, nor in the joint analysis.
However, when we analyzed the diplotypes and the phenotypes we found that the non-taster group had an increased risk
of colorectal cancer in comparison to the taster group. This association was borderline significant in the Czech population,
(OR= 1.28, 95% CI 0.99–1.67; Pvalue = 0.058) and statistically significant in the German population (OR= 1.36, 95% CI 1.06–
1.75; Pvalue = 0.016) and in the joint analysis (OR= 1.34, 95% CI 1.12–1.61; Pvalue = 0.001). In conclusion, we found a suggestive
association between the human bitter tasting phenotype and the risk of CRC in two different populations of Caucasian
origin.
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Introduction
Colorectal cancer (CRC) is the third most common cancer in the
world and the second in Europe [1,2]. Genetic background is
thought to play a role in modulating individual risk [3]. The main
interest of the research on the genetic susceptibility of CRC has
been focused on genes involved in xenobiotic transport and
metabolism [4,5,6,7], DNA repair and cell cycle [8,9], insulin
resistance, obesity and glucose levels [10], and inflammation
[11,12]. However, the possible association between taste receptors,
bitter sensing and CRC risk has been recently tested [13,14,15,16].
The gustatory system, developed during evolution, is a nutritional
gatekeeper of the body to determine which food should be ingested
and which should be rejected as potentially harmful. In particular,
the capability to discriminate bitter taste has evolved as a central
warning signal against the ingestion of possible toxic substances.
TAS2R38, the most studied gene belonging to this family, is greatly
involved in the ability to taste the glucosinolates, a large family of
bitter tasting compounds which are widely distributed in plants and
particularly in the Brassica sp. [17,18]. The discrimination of bitter
taste can influence the consumption of vegetables containing these
ligands and since a reduced vegetable intake can increase colon
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cancer risk, individual responsiveness to bitter compounds could
modulate the disease risk [19,20,21,22]. Moreover, bitter taste
receptors encoded by TAS2R gene family are expressed not only in
the tongue but also in the cells of the gastrointestinal (GI) tract
[23,24]. Taste receptors may provide, in this way, the organism with
two lines of defence against possible toxic agents. The first may be at
the level of taste in the tongue, by avoiding ingestion. The second
line of defence, the molecular sensing in the GI tract, could be
responsible for the detection of ingested harmful drugs and toxins,
thereby initiating responses critical for survival. Namely, the
detection process is initiated by sending messages to the nervous
system to give rise to the appropriate response of their neutralization
and expulsion [23]. Furthermore, the taste sensing is an important
system to start hormonal and/or neural pathways leading to the
regulation of caloric intake, pancreatic insulin secretion, and
metabolism [23]. Although these fundamental control systems have
been known since many years, the cellular and neural pathways that
mediate biological responses to luminal stimuli in general, and bitter
stimuli in particular, remain poorly characterized, However, recent
reports are quickly adding new information to this very important
topic [25,26,27,28].
TAS2R38 gene is characterized by three non synonymous
coding SNPs (rs713598 – G145C, Ala49Pro; rs1726866 – T785C,
Val262Ala; rs10246939 – A886G, Ile296Val). These three
polymorphisms, which are also tagging SNPs and cover all the
common genetic variability of the gene locus, give rise to several
haplotypes. Two of these haplotypes, Pro-Ala-Val (PAV) and Ala-
Val-Ile (AVI) are by far the most commonly found in human
populations [29,30,31]. Subjects possessing at least one copy of the
PAV allele are significantly more responsive to bitter tastants, like
PROP or PTC (taster phenotype), than those who are homozy-
gous for the AVI allele (non-taster phenotype). Since the distinct
phenotypes (taster vs non-taster) reflect a differential receptor
functionality, the inability to taste bitter compounds could be also
a marker for an impaired function of the receptors in GI: non-
taster individuals could react slower in eliminating xenobiotics in
the gut and consequently being at higher risk for CRC.
The aim of this study was, using a tagging approach, to evaluate
the possible correlation between all the common genetic variability
of TAS2R38 and the resulting ‘‘tasting ability’’ and CRC risk in a
total of 1203 cases of colorectal cancer and 1332 controls from the
German and Czech populations, which are known to exhibit one
of the higher incidence of CRC [32].
Results
In this case-control study we evaluated the variability in the
TAS2R38 gene in a group of subjects of German and Czech
Caucasian origin. Details regarding the main characteristics of the
two study populations are presented in Table 1.
Genotyping success rates and quality control
The genotype distributions at all loci were in Hardy-
Weinberg equilibrium in controls, with non-significant chi
square values (p.0.05, data not shown). Random duplicate
samples (8%) were also included and concordance of their
genotypes was greater than 99%. The average call rate for the
three SNPs was 97.9%.
Main effects of genotyped SNPs
The distribution of the genotypes and their odds ratios (ORs) for
association with CRC risk are shown in Table 2. We evaluated the
ORs separately and jointly for the two populations. We found that
there were no significant associations between the SNPs of the
TAS2R38 gene and CRC neither in the Czechs, in the Germans,
nor in the joint analysis.
Haplotype, diplotype and phenotype analysis
The distribution of the major haplotypes (PAV and AVI) was
not significantly different (p = 0.99) in the two populations.
Although rare haplotypes (AAV; PVV; AAI; PVI and PAI)
accounted for the same cumulative frequency (4%) for both the
German and the Czech groups, they appeared differently
distributed as reported in supplementary Figures S1 and S2.
Performing logistic regression analysis jointly on the German and
the Czech populations we observed a statistically significant
association between TAS2R38 diplotypes and CRC risk: carriers of
the AVI/AVI diplotype present an increased risk of CRC
compared to the PAV/PAV carriers with an OR of 1.33 (95%
CI 1.03–1.72; p = 0.027). Country of origin and gender did not
significantly modify the observed association (p = 0.85 and
p = 0.36 respectively) as reported in Table 3.
In the Czech population the carriers of the AVI/AVI diplotype
presented a statistically not significant tendency to increased CRC
risk, with an OR of 1.15 (95% CI 0.80–1.66; p = 0.44).
In the German population we found a significant association
between the AVI/AVI diplotype carriers and increased risk of
CRC with an OR of 1.52 (95% CI 1.05–2.21; p = 0.027)
compared to the PAV/PAV carriers.
Finally, we divided all the diplotypes in two groups defined by
their phenotype, the taster (PAV/PAV; PAV/PVV; P_*/A_*))
group and the non-taster ((AVI/AVI; AAV/AVI) group. Non-
tasters were associated with an increased risk of CRC in the
German population (OR = 1.36; 95% CI 1.06–1.75; p = 0.016).
Non-tasters were also associated with an increased risk in the
Czech population, although not at a statistically significant level
(OR = 1.28; 95% CI 0.99–1.67; p = 0.0580. Analyzing the two
populations together the association was stronger (OR = 1.34;
95% CI 1.12–1.61, p = 0.001.(Table 4)
Table 1. Characteristics of colorectal cancer patients and control subjects.
Populations Czech German Czech+German
Cases Controls Cases Controls Cases Controls
(n=601) (n=623) (n=602) (n=709) (n=1203) (n=1332)
Males/Females (%)* 57.3/42.7 53.9/46.1 49.7/50.3 49.2/50.8 53.5/46.5 51.4/48.6
Age Average 59.2 yrs 55.3 yrs 43.2 yrs 44.5 yrs 51.2 yrs 49.6 yrs
Lower Quartile 54.0 yrs 47.0 yrs 36.0 yrs 35.0 yrs 41.0 yrs 39.0 yrs
Upper quartile 67.0 yrs 65.0 yrs 49.0 yrs 53.0 yrs 63.0 yrs 59.0 yrs
doi:10.1371/journal.pone.0020464.t001
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Effects of genotyped SNPs in different population strata
For the Czech population we have performed analysis stratifying
for gender and smoking status and we also performed an analysis
using BMI as adjustment factor. For the German population we did
not have data on smoking and BMI. In our study there was no
difference in the genotype distributions in the various strata, nor
BMI had any effect on the association.
Discussion
In the present study common genetic variation in TAS2R38 was
completely captured. The applied intensive SNP tagging approach
provides a close to exhaustive analysis of associations of CRC risk
with common polymorphic variants known for the locus of interest.
Moreover the analyses of haplotypes, diplotype and phenotype
provide a comprehensive picture of the common genetic variability
of the TAS2R38 gene in relation with CRC risk.
In this study we had sufficient power (over 80% for a
codominant model) to detect OR = 1.30 at alpha = 0.05 for a
SNP with a MAF of 0.33 (which is the most rare allele hereby
studied) if considering only the German population. For the Czech
population we had the same power for detecting associations of
OR = 1.27 or greater and pooling together the two populations we
obtained sufficient power to detect more modest associations
(OR$1.21).
The present study provides interesting evidence on the possible
role of TAS2R38 in CRC risk. Analyzing the three SNPs
separately we did not find any association with CRC risk.
However, when we analyzed the distribution of major diplotypes
between the cases and the controls we found that the AVI/AVI
combination is associated with an increased CRC risk. This
association was stronger when considering the two population
together (p for the trend test = 0.007). Individuals carrying this
diplotype are referred as bitter compounds ‘‘non-tasters’’, as
opposed to ‘‘taster’’. We finally considered the non-taster
phenotype against all the others and found that it was associated
with increased CRC risk in both populations, although the
association was stronger in the German population than in the
Czech. This association suggests that the distinct phenotypes,
which reflect a differential receptor functionality in the inability to
taste bitter compounds, could be also a marker for an impaired
function of the receptors in GI: non-taster individuals could react
slower in eliminating xenobiotics in the gut and consequently
being at higher risk of CRC.
Possible limitations of this study include the relatively small sample
size and the possible differences between the two selected populations,
especially in the regard of possible confounding factors such as the
diet. However, we can confidently exclude a major role of ethnic
differences between the two populations. In a recent study Nelis and
colleagues investigated the underlying population stratification in
Europe showing that there were very little, if any, differences in the
genetic make-up of Germans and Czechs [32]. Moreover, the Czech
and the German populations also have a comparable CRC incidence
according to Globocan [1]. Dietary habits and food intake are not
dramatically different in the two countries (http://faostat.fao.org/
site/609/DesktopDefault.aspx?PageID=609). However we found a
Table 3. Associations of the TAS2R38 common diplotypes with colorectal cancer risk.
Czech population German population Combined population
Diplotype Casesa Controls OR (95%)b P value P trend Casesa Controls OR (95%)b P value P trend Casesa Controls OR (95%)b P value P trend
PAV/PAV 93 95 1 0.187 62 118 1 0.009 155 213 1 0.007
PAV/AVI 210 259 0.84
(0.60–1.19)
0.341 190 293 1.22
(0.85–1.75)
0.265 400 552 1.00
(0.78–1.28)
0.948
AVI/AVI 176 155 1.15
(0.80–1.66)
0.436 161 198 1.52
(1.05–2.21)
0.026 337 353 1.33
(1.03–1.72)
0.027
PAV/AVI+
AVI/AVI
386 414 0.96
(0.69–1.32)
0.819 351 491 1.34
(0.96–1.88)
0.084 737 905 1.13
(0.90–1.42)
0.278
aNumbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping were
resubmitted to up to two additional rounds of genotyping. Data points that were still not filled after this procedure were left blank.
bOR: odds ratio; CI: confidence interval.
doi:10.1371/journal.pone.0020464.t003
Table 4. Associations of bitter sensing phenotypes with colorectal cancer risk.
Czech population
(n =1069)
German population
(n=1091)
Czech+German population
(n =2160)
TASTER Cases Controls OR (95%) P value Cases Controls OR (95%) P value Cases Controls OR (95%) P value
PAV/PAV+PAV/PVV+P_*/A_* 343 395 1 260 436 1 603 831 1 -
Non-TASTER
AVI/AVI+AAV/AVI 176 155 1.28 (0.99–
1.67)
0.058 178 217 1.36 (1.06–
1.75)
0.016 354 372 1.34 (1.12–
1.61)
0.001
aNumbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping were
resubmitted to up to two additional rounds of genotyping. Data points that were still not filled after this procedure were left blank.
bOR: odds ratio; CI: confidence interval.
doi:10.1371/journal.pone.0020464.t004
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weaker association between the genetic variability of the locus and
CRC risk in the Czech population. One explanation may be related
to environmental factors (e.g. diet, smoking). A second explanation
could be the different enrollment strategy of study subjects since
Germans had a family history of CRC or CRC diagnosed under the
age of 50. Mean and median age are lower in the German population
and this may reflect the fact the causality of the tumour might have a
stronger genetic component since the environment had less time to
modify the cancer risk for these individuals. It is also possible that the
interactions between genes and environment could be the cause of the
weaker association in the Czech population in a way that we could
not detect within this study. Finally the association could be a chance
finding, but we would tend to exclude this for the fact that in the two
populations the association seems to indicate the same group as the
increased risk individuals.
Gender differences for bitter tastes have been explored [33] and
for these reason we conducted stratified analyses in both
populations. We found that sex was not a modifying factor in
either population.
Several genome-wide association studies (GWAS) on CRC risk
have been published [34], and in none TAS2R38 emerged as a
possible susceptibility locus. However, it is interesting to note that the
genomic region in which the TAS2R38 lies is poorly covered by the
SNP arrays used in published CRC GWAS. In particular, rs1726866
and rs10246939 are not present on those platforms (http://genome.
ucsc.edu/cgi-bin/hgGateway). We found an association by using the
combinations of the three genotypes into diplotypes, therefore it is not
surprising that GWAS, where two of the three SNPs were lacking,
and which do not routinely study haplotypes/diplotypes/phenotypes,
did not detect any signal at this locus.
In conclusion, we found a suggestive association between the
human bitter tasting phenotype and the risk of CRC in two
different populations of Caucasian origin. A larger, independent
study is needed to further investigate this finding.
Materials and Methods
Ethics Statement
All participants signed an informed written consent. The study
was approved by the ethical review boards of the institutions
responsible for subject recruitment in each of the recruitment
centres.
Written informed consent was obtained from all study partici-
pants. The ethical committees were the following:
Ethik Kommission der Medizinischen Fakulta¨t der Ruhr Uni-
versita¨t Bochum [Reg.-Nr.:1514]; Ethik Kommission – Medizinische
Fakulta¨t Bonn [Lfd. Nr. 115/09]; Ethik Kommission der Medizi-
nische Fakulta¨t der Technischen Universita¨t; Dresden [Bearbeitungs-
Nr. EK170102000]; Ethikkommission der Medizinische Fakulta¨t der
Heinrich Heine Universita¨t Du¨sseldorf [Studiennummer: 1172];
Ethikkommission I der Universita¨t - Medizinische Fakulta¨t Heidel-
berg [Antrags- Nr.: 220/2002]; Ethikkommission II an der Fakulta¨t
fu¨r Klinische Medizin der Ruprechts-Karl-Universita¨t Heidelberg
(concerning samples from Mannheim) [Antrags- Nr.: 87/04]
Ethikkommission der Medizinische Fakulta¨t Universita¨t Mu¨nchen
[Projekt Nr. 255/98]; Eticka´ komise U´stravu experimenta´lnı´ medicı´
AV CˇR Ethics Committee of the Institute for clinical and
Experimental Medicine and Faculty Thomayer Hospital [Cˇ.j. 786/
09 (09-04-09)].
Study populations
For the present cases-control study we have considered a group
of subjects from two populations: one from Czech Republic (601
cases, 623 controls) and the other from Germany (602 cases, 709
controls).
The Czech population has been extensively described elsewhere
[7]. Briefly, cases were CRC patients visiting nine oncological
departments (two in Prague, one each in Benesov, Brno, Liberec,
Ples, Pribram, Usti nad Labem, and Zlin) distributed in all
geographic regions of Czech Republic and being representative of
the population of the entire country. This study includes patients
who could be interviewed and provided biological samples of
sufficient quality for genetic analysis. All cases had histological
confirmation of their tumor diagnosis. In the group of cases, genetic
testing for hereditary nonpolyposis CRC (HNPCC) was recom-
mended to four patients, who belonged to families complying with
the Amsterdam criteria II, and these cases were excluded.
Controls were selected among patients admitted to five large
gastroenterological departments (Prague, Brno, Jihlava, Liberec,
and Pribram) all over the Czech Republic, during the same period
as the recruitment of cases. Only subjects whose colonoscopic
results were negative for malignancy, colorectal adenomas or IBD
were chosen as controls. Among 739 invited controls, a total of 623
(84.3%) were analyzed in this study (lost controls were similar to
those included with respect to sex distribution).
Cases included in this study had a mean age of 59.2 years (range
27–74), while controls had a mean age of 55.3 years (range 28–91).
The genetic analyses did not interfere with diagnostic or
therapeutic procedures for the subjects. All participants signed an
informed written consent and the design of the study was approved
by the Ethical Committee of the Institute of Experimental
Medicine, Prague, Czech Republic.
For the German population, as described in [35,36] CRC cases
comprised 602 index patients (age range 13–82 years, mean 43.2
years) recruited by six German university hospitals (Bochum,
Bonn, Dresden, Du¨sseldorf, Heidelberg and Munich/Regens-
burg). Cases were collected as part of a large study on susceptibility
to HNPCC. Inclusion criteria for the cases were (i) a family history
of CRC or (ii) CRC diagnosed under the age of 50. Analysis for
microsatellite instability was applied as a pre-screening test prior to
mutation analysis in the MSH2 and MLH1 genes. All cases were
tested to be microsatellite stable.
The control series consisted of 709 healthy, unrelated and
ethnicity-, sex- and age-matched blood donors (26–64 years, mean
44.5 years) which were recruited between 2004 and 2006 by the
Institute of Transfusion Medicine and Immunology, Faculty of
Mannheim, Germany. The matching intervals for age were
‘younger than 30 years’, five-year groups (30–34, 35–39,…,60–64)
and ‘older than 65 years’. Blood sampling was performed during
regular blood donation according to German guidelines. The
study was approved by the competent local Ethics Committees,
and written informed consent was obtained from all individuals.
Details regarding the main characteristics of the two study
populations are presented in Table 1.
Selection of tagging SNPs
We aimed at surveying the entire set of common genetic
variants in TAS2R38. To this end, we followed a hybrid tagging-
functional approach. We used the algorithm described by Carlson
and coworkers [37] that was developed to select the maximally
informative set of tag SNPs in a candidate-gene association study.
All polymorphisms in the region of TAS2R38 locus with minor
allele frequency (MAF) $5% in Caucasians from the International
HapMap Project (version 21a; http://www.hapmap.org) were
included. Tagging SNPs were selected with the use of the Tagger
program within Haploview (http://www.broad.mit.edu/mpg/
haploview/; http://www.broad.mit.edu/mpg/tagger/) [38,39],
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using pairwise tagging with a minimum r2 of 0.8. Considering that
the genomic region of TAS2R38 is characterized by high levels of
linkage disquilibrium (LD), we postulate that such SNPs are also
likely to tag any hitherto unidentified common SNPs in the gene.
We selected rs713598, rs1726866 and rs10246939 as tagging
SNPs since they are all non-synonymous functional
[29,30,40,41,42,43,44,45] SNPs.
DNA extraction and genotyping
DNA was extracted from blood samples with standard
proteinase K digestion followed by phenol/chloroform extraction
and ethanol precipitation. The order of DNAs of cases and
controls was randomized on PCR plates in order to ensure that an
equal number of cases and controls could be analyzed simulta-
neously. All genotyping was carried out using the Taqman assay.
The MGB Taqman probes and primers were purchased from
Applied Biosystems (Foster City, CA) as pre-designed assays. The
reaction mix included 10 ng genomic DNA, 10 pmol each primer,
2 pmol each probe and 2.5 ml of 2x master mix (Applied
Biosystems) in a final volume of 5 ml. The thermocycling included
40 cycles with 30 s at 95uC followed by 60 s at 60uC. PCR plates
were read on an ABI PRISM 7900HT instrument (Applied
Biosystems).
All samples that did not give a reliable result in the first round of
genotyping were resubmitted to up to two additional rounds of
genotyping. Data points that were still not filled after this
procedure were left blank.
Haplotype and diplotype reconstruction
Haplotypes and diplotypes were reconstructed using PHASE
software [46].
Statistical Analysis
The frequency distribution of genotypes was examined for the
cases and the controls. Hardy-Weinberg equilibrium was tested in
the cases and in the controls and in the two populations separately
by chi square test. We used logistic regression for multivariate
analyses to assess the main effects of the genetic polymorphism on
CRC risk using a co-dominant and a dominant inheritance model.
The most common genotype in the controls was assigned as the
reference category. All analyses were adjusted for age and gender.
In the Czech population we also adjusted for Body Max Index
(BMI) as a continuous variable. We analyzed the two populations
separately and together (we adjusted also for center of recruitment
in the latter case).
Logistic regression considering the reconstructed haplotype
adjusted for age (continuous), sex and study center was performed
to calculate risk estimates. The ‘‘taster’’ (PAV) haplotype was set as
reference group. We finally created diplotypes for each individual
and grouped and divided them into two phenotypic groups, the
taster group ((PAV/PAV; PAV/PVV; P_*/A_*) and the non-
taster group (AVI/AVI;AAV/AVI). For the diplotype analysis the
‘‘taster’’ group was set as reference.
We also performed stratified analysis for gender and smoking
habits. Smokers were classified as current smokers, ex smokers
(quit smoking for more than 5 years) or never smokers. Smokers
were subsequently divided in heavy smokers (more than 20
cigarettes per day) and non-heavy smokers (less than 20 cigarettes
per day). All analysis were performed using STATGRAPHICSH
Centurion XVI software ( 2009 by StatPoint Technologies,
Inc.www.STATGRAPHICS.com) and STATA software (Stata-
Corp, College Station, TX).
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